Cervomed Inc (CRVO)

Aug 10, 2026, 7:30 AM EDT - 1 day ago

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

2026-08-10T11:05:44.000Z - 1 day ago

CervoMed price target lowered to $18 from $27 at Canaccord

Aug 7, 2026, 7:00 AM EDT - 4 days ago

CervoMed Quarterly report: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 4 days ago

CervoMed Earnings release: Q2 2026

Aug 5, 2026, 7:30 AM EDT - 6 days ago

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

Aug 4, 2026, 5:15 AM EDT - 7 days ago

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Jul 14, 2026, 7:30 AM EDT - 4 weeks ago

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

2026-07-09T11:40:46.000Z - 4 weeks ago

CervoMed completes enrollment in neflamapimod study

Jul 9, 2026, 7:30 AM EDT - 4 weeks ago

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

2026-07-06T21:05:17.000Z - 5 weeks ago

CervoMed registers to sell 10.08M shares of common stock for holders

Jul 6, 2026, 8:00 AM EDT - 5 weeks ago

CervoMed Registration statement: Registration filing

Jul 6, 2026, 7:30 AM EDT - 5 weeks ago

CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026

Jun 22, 2026, 4:05 PM EDT - 7 weeks ago

CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

2026-06-18T16:40:10.000Z - 7 weeks ago

CervoMed announces $10M registered direct offering priced at-the-market

Jun 18, 2026, 12:35 PM EDT - 7 weeks ago

CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

2026-06-18T11:11:15.000Z - 7 weeks ago

CervoMed receives notice of allowance from USPTO on neflamapimod

Jun 18, 2026, 7:00 AM EDT - 7 weeks ago

CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042

Jun 15, 2026, 7:00 AM EDT - 2 months ago

CervoMed Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 15, 2026, 7:00 AM EDT - 2 months ago

CervoMed Slides: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 12, 2026, 7:30 AM EDT - 2 months ago

CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

2026-06-10T11:44:51.000Z - 2 months ago

CervoMed announces $10.5M private placement

2026-06-10T11:41:14.000Z - 2 months ago

CervoMed announces $10.5M private placement

Jun 10, 2026, 7:30 AM EDT - 2 months ago

CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies

Jun 10, 2026, 7:00 AM EDT - 2 months ago

CervoMed Slides: Corporate presentation

2026-05-18T21:35:08.000Z - 3 months ago

CervoMed price target lowered to $9 from $11 at Roth Capital

May 18, 2026, 7:30 AM EDT - 3 months ago

CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 15, 2026, 7:00 AM EDT - 3 months ago

CervoMed Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

CervoMed Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

CervoMed Proxy statement: Proxy filing

2026-04-22T14:32:59.000Z - 3 months ago

CervoMed presents neflamapimod MRI data

Apr 22, 2026, 7:30 AM EDT - 3 months ago

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

Apr 7, 2026, 7:30 AM EDT - 4 months ago

CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting

Mar 23, 2026, 3:00 PM EDT - 5 months ago

CervoMed Transcript: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 5 months ago

CervoMed Slides: The 38th Annual Roth Conference

2026-03-19T11:56:17.000Z - 5 months ago

CervoMed’s neflamapimod shows efficacy in dementia with DLB

Mar 19, 2026, 7:30 AM EDT - 5 months ago

CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology

2026-03-17T23:00:26.000Z - 5 months ago

CervoMed price target lowered to $11 from $19 at Roth Capital

2026-03-17T22:25:46.000Z - 5 months ago

CervoMed price target raised to $21 from $15 at Chardan

Mar 17, 2026, 4:00 PM EDT - 5 months ago

CervoMed Earnings release: Q4 2025

Mar 17, 2026, 4:00 PM EDT - 5 months ago

CervoMed Annual report: Q4 2025

2026-03-17T11:46:53.000Z - 5 months ago

CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024

Mar 17, 2026, 7:30 AM EDT - 5 months ago

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Mar 17, 2026, 7:00 AM EDT - 5 months ago

CervoMed Slides: Corporate presentation

2026-03-12T11:27:04.000Z - 5 months ago

CervoMed announces presentations at AP/PD 2026 scientific conference

2026-03-04T12:41:24.000Z - 5 months ago

CervoMed completes Phase 1 volunteer study for neflamapimod

Mar 4, 2026, 7:30 AM EST - 5 months ago

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

2026-02-18T11:16:19.000Z - 6 months ago

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform

Feb 17, 2026, 8:00 AM EST - 6 months ago

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

SCYX

2025-12-18T11:40:57.000Z - 8 months ago

CervoMed initiated with an Overweight at Cantor Fitzgerald

2025-12-04T22:05:45.000Z - 8 months ago

CervoMed’s neflamapimod shows efficacy in slowing dementia

Dec 4, 2025, 5:00 PM EST - 8 months ago

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

2025-12-02T12:11:05.000Z - 9 months ago

CervoMed presents new data from Phase 2b RewinD-LB trial on neflamapimod

Dec 2, 2025, 7:00 AM EST - 9 months ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Nov 24, 2025, 7:00 AM EST - 9 months ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 7, 2025, 7:00 AM EST - 9 months ago

CervoMed Earnings release: Q3 2025

Nov 7, 2025, 7:00 AM EST - 9 months ago

CervoMed Quarterly report: Q3 2025

Oct 22, 2025, 11:25 AM EDT - 10 months ago

CervoMed Transcript: Emerging Growth Conference

Oct 20, 2025, 8:00 AM EDT - 10 months ago

CervoMed to Present at the Emerging Growth Conference

Oct 8, 2025, 7:00 AM EDT - 10 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 2, 2025, 8:00 AM EDT - 11 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 7:30 AM EDT - 11 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 8, 2025, 2:00 PM EDT - 1 year ago

CervoMed Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 1 year ago

CervoMed to Participate in Upcoming Investor Conferences

Aug 8, 2025, 4:00 PM EDT - 1 year ago

CervoMed Earnings release: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 1 year ago

CervoMed Quarterly report: Q2 2025

Jul 28, 2025, 8:00 AM EDT - 1 year ago

CervoMed Transcript: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

CervoMed Press release: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

CervoMed Slides: Status Update

Jul 28, 2025, 7:00 AM EDT - 1 year ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 1 year ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

Jun 25, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Corporate Presentation

May 28, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Corporate Presentation

May 20, 2025, 5:00 PM EDT - 1 year ago

CervoMed Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

CervoMed Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

CervoMed Quarterly report: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 29, 2025, 8:00 AM EDT - 1 year ago

CervoMed Proxy statement: Proxy Filing

Apr 5, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Investor Presentation

Mar 25, 2025, 8:00 AM EDT - 1 year ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 18, 2025, 4:00 PM EDT - 1 year ago

CervoMed Earnings release: Q4 2024

Mar 18, 2025, 4:00 PM EDT - 1 year ago

CervoMed Annual report: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

CervoMed Slides: Investor Presentation

Mar 10, 2025, 4:05 PM EDT - 1 year ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 31, 2025, 7:00 AM EST - 1 year ago

CervoMed Slides: Investor Presentation

Jan 29, 2025, 8:00 AM EST - 1 year ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 19, 2024, 3:00 PM EST - 1 year ago

CervoMed Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Quarterly report: Q3 2024

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 3, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing

Oct 2, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Sep 6, 2024, 1:50 PM EDT - 2 years ago

CervoMed Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 22, 2024, 8:00 AM EDT - 2 years ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Aug 13, 2024, 12:30 PM EDT - 2 years ago

CervoMed Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 12, 2024, 4:00 PM EDT - 2 years ago

CervoMed Quarterly report: Q2 2024

Aug 12, 2024, 4:00 PM EDT - 2 years ago

CervoMed Earnings release: Q2 2024

Jul 30, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 23, 2024, 10:00 AM EDT - 2 years ago

CervoMed Transcript: Status Update

Jul 22, 2024, 8:00 AM EDT - 2 years ago

CervoMed Slides: Corporate Presentation

Jul 17, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 2 years ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 2 years ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 30, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing

May 20, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 14, 2024, 6:00 PM EDT - 2 years ago

CervoMed Quarterly report: Q1 2024

May 14, 2024, 6:00 PM EDT - 2 years ago

CervoMed Earnings release: Q1 2024

May 10, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

CervoMed Proxy statement: Proxy Filing

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates